Advance Search
DAI Shuhua, TENG Yongshi, JIANG Yushu, QIN Lingzhi, XUE Hongfei, XU Jiajia, LI Wei. Research progress on risk factors of recurrence of neuromyelitis optica spectrum disorders[J]. Journal of Clinical Medicine in Practice, 2023, 27(8): 126-129, 134. DOI: 10.7619/jcmp.20223787
Citation: DAI Shuhua, TENG Yongshi, JIANG Yushu, QIN Lingzhi, XUE Hongfei, XU Jiajia, LI Wei. Research progress on risk factors of recurrence of neuromyelitis optica spectrum disorders[J]. Journal of Clinical Medicine in Practice, 2023, 27(8): 126-129, 134. DOI: 10.7619/jcmp.20223787
shu

Research progress on risk factors of recurrence of neuromyelitis optica spectrum disorders

  • 1.

    Xinxiang Medical University, Xinxiang, Henan, 453003

  • 2.

    Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003

  • 3.

    Zhengzhou University, Zhengzhou, Henan, 450000

  • 4.

    Henan University, Zhengzhou, Henan, 450046

More Information
  • Received Date: December 19, 2022
  • Revised Date: March 02, 2023
  • Available Online: May 10, 2023
    Graphical Abstract
    • Abstract

  • Neuromyelitis optica spectrum disorders (NMOSD) is a rare, highly recurrent and disabling primary inflammatory demyelinating disease of central nervous system. Recurrent neurological dysfunction in patients can gradually promote the accumulation of symptoms, and ultimately resulting in irreparable clinical outcomes. Therefore, prevention of recurrence has become a key factor in the treatment of NMOSD, and it is urgent to elucidate the characteristics and pathological mechanisms of recurrence. However, it is currently rarely known about the potential factors that affect the frequency, severity and form of recurrence in NMOSD patients. In this paper, the research progress on recurrence-related factors of NMOSD was reviewed in order to provide reference for recurrence assessment of NMOSD.

    • FullText(HTML)
    • References (43)
  • [1]
    WEINSHENKER B G, WINGERCHUK D M. Neuromyelitis spectrum disorders[J]. Mayo Clin Proc, 2017, 92(4): 663-679. doi: 10.1016/j.mayocp.2016.12.014
    [2]
    中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436. doi: 10.3969/j.issn.1006-2963.2021.06.002
    [3]
    FUJIHARA K, BENNETT J L, DE SEZE J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(5): e841. doi: 10.1212/NXI.0000000000000841
    [4]
    LEVY M, FUJIHARA K, PALACE J. New therapies for neuromyelitis optica spectrum disorder[J]. Lancet Neurol, 2021, 20(1): 60-67. doi: 10.1016/S1474-4422(20)30392-6
    [5]
    PAPP V, MAGYARI M, AKTAS O, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review[J]. Neurology, 2021, 96(2): 59-77.
    [6]
    SUN H, SUN X, LI J, et al. Gender differences among Chinese patients with neuromyelitis optica spectrum disorders[J]. Mult Scler Relat Disord, 2017, 17: 5-8. doi: 10.1016/j.msard.2017.06.008
    [7]
    WINGERCHUK D M, HOGANCAMP W F, O'BRIEN P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome)[J]. Neurology, 1999, 53(5): 1107-1114. doi: 10.1212/WNL.53.5.1107
    [8]
    PALACE J, LIN D Y, ZENG D L, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323. doi: 10.1093/brain/awz054
    [9]
    HUANG Y L, WANG Y G, ZHOU Y F, et al. Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China[J]. J Neurol Sci, 2017, 372: 152-156. doi: 10.1016/j.jns.2016.11.054
    [10]
    KUNCHOK A, MALPAS C, NYTROVA P, et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2020, 38: 101868. doi: 10.1016/j.msard.2019.101868
    [11]
    COLLONGUES N, MARIGNIER R, JACOB A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset[J]. Mult Scler, 2014, 20(8): 1086-1094. doi: 10.1177/1352458513515085
    [12]
    FUJIHARA K. Neuromyelitis optica spectrum disorders: still evolving and broadening[J]. Curr Opin Neurol, 2019, 32(3): 385-394. doi: 10.1097/WCO.0000000000000694
    [13]
    MAO Z F, YIN J J, ZHONG X N, et al. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population[J]. BMC Neurol, 2015, 15: 160. doi: 10.1186/s12883-015-0417-y
    [14]
    MEALY M A, MOSSBURG S E, KIM S H, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions[J]. Mult Scler Relat Disord, 2019, 28: 64-68. doi: 10.1016/j.msard.2018.12.011
    [15]
    SEPULVEDA M, DELGADO-GARCÍA G, BLANCO Y, et al. Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6(6): e607. doi: 10.1212/NXI.0000000000000607
    [16]
    CARNERO CONTENTTI E, DACCACH MARQUES V, SOTO DE CASTILLO I, et al. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort[J]. J Neurol, 2020, 267(5): 1260-1268. doi: 10.1007/s00415-020-09699-2
    [17]
    CHANG V W, CHANG H M. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder[J]. Neuropathol Appl Neurobiol, 2020, 46(3): 199-218. doi: 10.1111/nan.12574
    [18]
    STELLMANN J P, KRUMBHOLZ M, FRIEDE T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response[J]. J Neurol Neurosurg Psychiatry, 2017, 88(8): 639-647. doi: 10.1136/jnnp-2017-315603
    [19]
    ZHANG W H, CUI L, ZHANG Y Q, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population[J]. J Neurol, 2020, 267(4): 1197-1205. doi: 10.1007/s00415-019-09685-3
    [20]
    AKAISHI T, TAKAHASHI T, HIMORI N, et al. Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders[J]. J Neuroimmunol, 2020, 340: 577168. doi: 10.1016/j.jneuroim.2020.577168
    [21]
    AKAISHI T, TAKAHASHI T, NAKASHIMA I, et al. Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)[J]. J Neurol Sci, 2020, 410: 116671. doi: 10.1016/j.jns.2020.116671
    [22]
    刘楚楚, 黄洁, 刘雨辉, 等. 视神经脊髓炎谱系病的危险因素与复发特点临床分析[J]. 中华全科医学, 2021, 19(5): 715-718, 829. doi: 10.16766/j.cnki.issn.1674-4152.001899
    [23]
    PEREIRA W L C J, REICHE E M V, KALLAUR A P, et al. Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica[J]. Acta Neuropsychiatr, 2017, 29(3): 170-178. doi: 10.1017/neu.2016.49
    [24]
    LIN L Y, HANG H L, ZHANG J H, et al. Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders[J]. Mult Scler Relat Disord, 2022, 58: 103494. doi: 10.1016/j.msard.2022.103494
    [25]
    LI H Y, DAI Y Q, WU A M, et al. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders[J]. J Neuroimmunol, 2015, 281: 38-43. doi: 10.1016/j.jneuroim.2015.02.014
    [26]
    HOU M M, LI Y F, HE L L, et al. Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: a meta-analysis[J]. Int Immunopharmacol, 2019, 75: 105793. doi: 10.1016/j.intimp.2019.105793
    [27]
    DOS PASSOS G R, SATO D K, BECKER J, et al. Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications[J]. Mediators Inflamm, 2016, 2016: 5314541.
    [28]
    UZAWA A, MORI M, SATO Y, et al. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse[J]. J Neurol Neurosurg Psychiatry, 2012, 83(3): 339-340. doi: 10.1136/jnnp.2011.241760
    [29]
    BARROS P O, CASSANO T, HYGINO J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase[J]. Clin Exp Immunol, 2016, 183(3): 480-489. doi: 10.1111/cei.12733
    [30]
    TRABOULSEE A, GREENBERG B M, BENNETT J L, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2020, 19(5): 402-412. doi: 10.1016/S1474-4422(20)30078-8
    [31]
    贾琳琳, 蒋玙姝, 张梦歌, 等. 视神经脊髓炎谱系疾病发病机制的研究进展[J]. 实用临床医药杂志, 2022, 26(7): 132-138. doi: 10.7619/jcmp.20215000
    [32]
    TAHARA M, OEDA T, OKADA K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2020, 19(4): 298-306. doi: 10.1016/S1474-4422(20)30066-1
    [33]
    CHA E, LEE K M, PARK K D, et al. Hydroxycholesterol levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with picolinic derivatization: increased levels and association with disability during acute attack[J]. PLoS One, 2016, 11(12): e0167819. doi: 10.1371/journal.pone.0167819
    [34]
    WU K M, WEN L L, DUAN R R, et al. Triglyceride level is an independent risk factor in first-attacked neuromyelitis optica spectrum disorders patients[J]. Front Neurol, 2019, 10: 1230. doi: 10.3389/fneur.2019.01230
    [35]
    SHU Y, ZHANG L, CHANG Y, et al. Association of serum Cystatin C with neuromyelitis optica spectrum disorders[J]. Eur J Neurol, 2018, 25(7): 999-1002. doi: 10.1111/ene.13646
    [36]
    WINGERCHUK D M, BANWELL B, BENNETT J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. doi: 10.1212/WNL.0000000000001729
    [37]
    MURCHISON A, KITLEY J, LEITE M I, et al. Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease[J]. J Neurol Sci, 2015, 355(1/2): 49-53.
    [38]
    ZHANG J H, LIU F, WANG Y Q, et al. Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: two new cases[J]. Mult Scler, 2017, 23(14): 1950-1954. doi: 10.1177/1352458517705479
    [39]
    NAKAMURA Y, LIU Z, FUKUMOTO S, et al. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder[J]. Eur J Neurol, 2020, 27(1): 92-99. doi: 10.1111/ene.14038
    [40]
    ORMAN G, WANG K Y, PEKCEVIK Y, et al. Enhancing brain lesions during acute optic neuritis and/or longitudinally extensive transverse myelitis may portend a higher relapse rate in neuromyelitis optica spectrum disorders[J]. AJNR Am J Neuroradiol, 2017, 38(5): 949-953. doi: 10.3174/ajnr.A5141
    [41]
    YAMAMURA T, KLEITER I, FUJIHARA K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381(22): 2114-2124. doi: 10.1056/NEJMoa1901747
    [42]
    LUO J R, YU J S, SUI Z C, et al. Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: a modeling analysis of literature aggregate data[J]. Int Immunopharmacol, 2022, 110: 109004. doi: 10.1016/j.intimp.2022.109004
    [43]
    HOUZEN H, KONDO K, NIINO M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan[J]. Neurology, 2017, 89(19): 1995-2001. doi: 10.1212/WNL.0000000000004611
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (243) PDF downloads (27) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return